SKYE BIOSCIENCE INC(SKYE) Stock Price Today

US Stock MarketDetailed Quotes

SKYE BIOSCIENCE INC (SKYE)

Watchlist

0.5926
0.00000.00%

Trading Mar 31 09:59 ET

19.78MMarket Cap-0.42P/E (TTM)

SKYE Stock Chart

Real-Time

5D
Daily
Weekly
Monthly
1Q
1Y

SKYE Orderflow

Unit: --

SKYE Orderflow Trend

IntradayDayWeekMonth

No Data

SKYE BIOSCIENCE INC (SKYE) News

Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice
TipRanksMar 19 18:02 ET
12 Health Care Stocks Moving In Monday's After-Market Session
BenzingaMar 16 17:05 ET
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Skye Bioscience (SKYE)
TipRanksMar 12 04:31 ET · Ratings
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
Yahoo FinanceMar 11 21:04 ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
BenzingaMar 11 13:06 ET
Express News | Skye Bioscience Shares Are Trading Lower After the Company Reported a Q4 EPS Miss
BenzingaMar 11 12:12 ET

SKYE BIOSCIENCE INC (SKYE) Stock Forum

喝不起气水

Mar 10 18:16

$SKYE BIOSCIENCE INC (SKYE.US)$ 666

Trytosaveabit

Feb 2 20:04

news

$SKYE BIOSCIENCE INC (SKYE.US)$ Reuters
1m
Skye Reports Positive Cbeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide!
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab doses
Weight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost ...

Trytosaveabit

Jan 23 19:13

Heads-Up! Thought maybe time to let ya know dis coming! Hehehe C&P from notes!

$SKYE BIOSCIENCE INC (SKYE.US)$ Data from the 26-week extension is expected in Q1 2026 and will provide information on the potential full treatment duration of 52 weeks followed by a 12-week follow-up period.

ROI HIGH

Jan 8 20:11

$SKYE BIOSCIENCE INC (SKYE.US)$

Trytosaveabit

Jan 5 20:01

news

$SKYE BIOSCIENCE INC (SKYE.US)$ Reuters
just
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated With Enhanze® for Obesity